BioLineRx (NASDAQ:BLRX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

Posted by Tyrone Williams on Jun 12th, 2026

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.88 and traded as high as $3.29. BioLineRx shares last traded at $3.28, with a volume of 4,860 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

View Our Latest Stock Analysis on BioLineRx

BioLineRx Stock Performance

The stock has a market capitalization of $14.73 million, a PE ratio of -1.76 and a beta of 1.53. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The firm has a 50 day moving average of $2.84 and a 200-day moving average of $2.89.

BioLineRx (NASDAQ:BLRX – Get Free Report) last released its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.68. The company had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.

About BioLineRx

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.